Tenofovir DF + Emtricitabine + Rilpivirine

Form: Tablet

Strength: TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg

Reference Brands: Complera(US); Eviplera(EU)

Category: Anti Viral

Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Rilpivirine is a once-daily, fixed-dose combination used for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. Marketed under the brand names Complera (US) and Eviplera (EU), it combines three powerful antiretroviral agents: TDF (a nucleotide reverse transcriptase inhibitor), Emtricitabine (an NRTI), and Rilpivirine (a non-nucleoside reverse transcriptase inhibitor). This single-tablet regimen simplifies HIV treatment, enhances patient adherence, and effectively suppresses viral load. Approved by the FDA and EMA, it is recommended for patients without resistance to any of its components and should be taken with a meal for optimal absorption.